GA
HRTX icon

Gagnon Advisors’s Heron Therapeutics HRTX Stock Holding History

Gagnon Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-576,206
Closed -$2.43M – 30
2022
Q3 		$2.43M Buy
+576,206
New +$2.25M 1.57% 24

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Gagnon Advisors's HRTX Position: Q4 2022 in Review

Gagnon Advisors sold out of Heron Therapeutics (HRTX) in Q4 2022, closing a stake of 576,206 shares — an estimated $2.43M sold.

Gagnon Advisors first reported a position in HRTX in Q3 2022 and held it in 1 quarter. The position peaked at $2.43M in Q3 2022. 176 funds tracked by Wall St. Rank hold HRTX as of Q4 2022.

  • Gagnon Advisors reported no remaining Heron Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Gagnon Advisors sold 576,206 Heron Therapeutics shares in Q4 2022, an estimated $2.43M.
  • Gagnon Advisors first reported a position in Heron Therapeutics in Q3 2022 and held it in 1 quarter.
  • Gagnon Advisors's Heron Therapeutics position peaked at $2.43M in Q3 2022.
  • 176 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2022.

Based on Gagnon Advisors's 13F filing for Q4 2022, filed 7 Feb 2023.